CXCL12 and hepatocellular carcinoma: Dual treatment also significantly alleviated tumor-associated fibrosis and inhibited the activation of HSCs by blocking the expression and secretion of SDF-1α in HCC cells, and subsequently inhibited the MAPK pathway in HSCs (Figure 6G).